Skip to main content
SpringerLink
Log in

Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Definitively Does not Deserve Its Bad Reputation

  • Peritoneal Surface Malignancy
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Überrück L, Nadiradze G, Yurttas C, et al. In-hospital mortality and complication rates according to health insurance data in patients undergoing hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies in Germany. Ann Surg Oncol. Epub ahead of print November 9, 2020. https://doi.org/10.1245/s10434-020-09301-z.

  2. Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.

    Article  Google Scholar 

  3. Piso P, Nedelcut SD, Rau B, et al. Morbidity and mortality following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: data from the DGAV StuDoQ registry with 2149 consecutive patients. Ann Surg Oncol. 2019;26:148–54.

    Article  Google Scholar 

  4. Noiret B, Clement G, Lenne X, et al. Centralization and oncologic training reduce postoperative morbidity and failure-to-rescue rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: study on a 10-year national French practice. Ann Surg. Epub ahead of print August 21, 2020. https://doi.org/10.1097/SLA.0000000000004326.

  5. El Amrani M, Lenne X, Clement G, et al. Specificity of procedure volume and its association with postoperative mortality in digestive cancer surgery: a nationwide study of 225,752 patients. Ann Surg. 2019;270:775–82.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France

    B. Noiret MD, G. Piessen MD, PhD & C. Eveno MD, PhD

  2. UMR-S1277 – CANTHER Laboratory “Cancer Heterogeneity, Plasticity and Resistance to Therapies”, Lille, France

    G. Piessen MD, PhD & C. Eveno MD, PhD

Authors
  1. B. Noiret MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Piessen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Eveno MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Eveno MD, PhD.

Ethics declarations

Disclosure

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Noiret, B., Piessen, G. & Eveno, C. Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Definitively Does not Deserve Its Bad Reputation. Ann Surg Oncol 28, 5448–5449 (2021). https://doi.org/10.1245/s10434-021-09741-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-09741-1

Search

Navigation